Announcements Trials
Browse Landscape

Phase

Phase 1 9Phase 2 3Phase NA 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 1

Conditions

Glioblastoma 6Central Nervous System Neoplasms 5Gliosarcoma 4Brain Neoplasms 4Glioma 3Astrocytoma 3Sarcoma 1Rectal Neoplasms 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Melanoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Temozolomide 37Radiotherapy 20Bevacizumab 14Carboplatin 10Magnetic Resonance Spectroscopy 9Carmustine 9antineoplaston AS 2-1 8antineoplaston A10 8Irinotecan 8Filgrastim 7Cyclophosphamide 6Cisplatin 6Etoposide 5sargramostim 4Vincristine 4Thiotepa 4Surgical Procedures, Operative 4Specimen Handling 4Radiation 4Peripheral Blood Stem Cell Transplantation 4Lomustine 4Everolimus 4Chemotherapy, Adjuvant 4trametinib 3aldesleukin 3Topotecan 3Thalidomide 3Tamoxifen 3Sunitinib 3Procarbazine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Astrocytoma × O(6)-benzylguanine × Clear all
NCT00005081 2014-08-21

Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma

Duke University

Phase 2 Completed
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00613093 2014-07-09

Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma

Duke University

Phase 2 Completed
67 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Central Nervous System Neoplasms

NCT00389090 2012-02-09

A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma

Keryx / AOI Pharmaceuticals, Inc.

Phase 2 Terminated
32 enrolled
CNS

Astrocytoma, Glioma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡